Showing results (51-60 of 72) with videos related to
Sort By:
Pageof 8
Biotechnology and Bioengineering|August 27, 2017
Biosimilars: Key regulatory considerations and similarity assessment toolsCarol F Kirchhoff, Xiao-Zhuo Michelle Wang, Hugh D Conlon, et al.The Canadian Veterinary Journal = La Revue Veterinaire Canadienne|February 6, 2020
A survey of veterinarian mental health and resilience in Ontario, CanadaColleen O Best, Jennifer L Perret, Joanne Hewson, et al.Journal of the American Academy of Dermatology|February 19, 2008
Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patientsJoseph D Conlon, Marie Dauenhauer, Viseslav Tonkovic-Capin, et al.The AAPS Journal|October 7, 2016
Statistical Approaches to Assess Biosimilarity from Analytical DataRichard Burdick, Todd Coffey, Hiten Gutka, et al.Biotechnology and Bioengineering|June 20, 1995
Two-step immobilized enzyme conversion of cephalosporin C to 7-aminocephalosporanic acidH D Conlon, J Baqai, K Baker, et al.Veterinary Evidence|April 20, 2026
Personal health and nutrition information-seeking attitudes and behaviours of first year Canadian and United States veterinary studentsShelby A Nielson, May K Kamleh, Peter D Conlon, et al.Journal of Veterinary Medical Education|March 3, 2021
Understanding Incoming Canadian and US Veterinary Students' Attitudes and Perceptions of Their Dietary Habits and Levels of Physical ActivityShelby A Nielson, May K Kamleh, Peter D Conlon, et al.Journal of the American College of Cardiology|October 1, 1984
Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyocardial biopsy and response to immunosuppressionP A Vignola, K Aonuma, P S Swaye, et al.Journal of Cellular Physiology|August 1, 1994
Differential effects of warfarin on mRNA levels of developmentally regulated vitamin K dependent proteins, osteocalcin, and matrix GLA protein in vitroL M Barone, M A Aronow, M S Tassinari, et al.Therapeutic Advances in Gastroenterology|June 22, 2019
The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference productJoseph E McClellan, Hugh D Conlon, Michael W Bolt, et al.Pageof 8